Sees FY19 Suboxone and Sandoz Authorized Generic manufacturing volume of $23M-$30M; non-GAAP gross margins of 70% to 72% on total revenues; non-GAAP adjusted EBITDA loss of $40M-$45M; and cash burn of approximately $45M-$50M after considering interest, capital spending and working capital effects, but prior to any non-dilutive capital transactions.
https://thefly.com/landingPageNews.php?id=2879039
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.